Evidence map›Paper›PMID 25260367›Full record

ReviewThe oncologist2014

Novel approaches in anaplastic thyroid cancer therapy.

Kun-Tai Hsu, Xiao-Min Yu, Anjon W Audhya, Juan C Jaume, Ricardo V Lloyd, Shigeki Miyamoto, Tomas A Prolla, Herbert Chen

Open access · bronzeAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The oncologist, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 54 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Emerging Roles of Circular RNAs in Thyroid Cancer.Frontiers in cell and developmental biology · 2021
    Review
  13. Notch Signaling in Thyroid Cancer.Advances in experimental medicine and biology · 2021
    Review
  14. Article
  15. Article
  16. Article
  17. Immunotherapy in anaplastic thyroid cancer.American journal of translational research · 2020
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Kun-Tai HsuEndocrine Surgery Research Laboratories, Department of Surgery, Department of Biomolecular Chemistry, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Department of Pathology and Laboratory Medicine, Department of Oncology, Department of Genetics and Medical Genetics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Xiao-Min YuEndocrine Surgery Research Laboratories, Department of Surgery, Department of Biomolecular Chemistry, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Department of Pathology and Laboratory Medicine, Department of Oncology, Department of Genetics and Medical Genetics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Anjon W AudhyaEndocrine Surgery Research Laboratories, Department of Surgery, Department of Biomolecular Chemistry, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Department of Pathology and Laboratory Medicine, Department of Oncology, Department of Genetics and Medical Genetics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Juan C JaumeEndocrine Surgery Research Laboratories, Department of Surgery, Department of Biomolecular Chemistry, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Department of Pathology and Laboratory Medicine, Department of Oncology, Department of Genetics and Medical Genetics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Ricardo V LloydEndocrine Surgery Research Laboratories, Department of Surgery, Department of Biomolecular Chemistry, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Department of Pathology and Laboratory Medicine, Department of Oncology, Department of Genetics and Medical Genetics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Shigeki MiyamotoEndocrine Surgery Research Laboratories, Department of Surgery, Department of Biomolecular Chemistry, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Department of Pathology and Laboratory Medicine, Department of Oncology, Department of Genetics and Medical Genetics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Tomas A ProllaEndocrine Surgery Research Laboratories, Department of Surgery, Department of Biomolecular Chemistry, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Department of Pathology and Laboratory Medicine, Department of Oncology, Department of Genetics and Medical Genetics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.
Herbert ChenEndocrine Surgery Research Laboratories, Department of Surgery, Department of Biomolecular Chemistry, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, Department of Pathology and Laboratory Medicine, Department of Oncology, Department of Genetics and Medical Genetics, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA chen@surgery.wisc.edu.
University of Wisconsin–Madison · US

Funding

NCI NIH HHS R01 CA121115
6 · The paper itself

Abstract

Anaplastic thyroid cancer (ATC), accounting for less than 2% of all thyroid cancer, is responsible for the majority of death from all thyroid malignancies and has a median survival of 6 months. The resistance of ATC to conventional thyroid cancer therapies, including radioiodine and thyroid-stimulating hormone suppression, contributes to the very poor prognosis of this malignancy. This review will cover several cellular signaling pathways and mechanisms, including RET/PTC, RAS, BRAF, Notch, p53, and histone deacetylase, which are identified to play roles in the transformation and dedifferentiation process, and therapies that target these pathways. Lastly, novel approaches and agents involving the Notch1 pathway, nuclear factor κB, Trk-fused gene, cancer stem-like cells, mitochondrial mutation, and tumor immune microenvironment are discussed. With a better understanding of the biological process and treatment modality, the hope is to improve ATC outcome in the future.

Indexed as

Biomarkers, TumorGenetic TherapyHistone Deacetylase InhibitorsHistone DeacetylasesHumansMolecular Targeted TherapyNF-kappa BProtein Kinase InhibitorsProto-Oncogene Proteins c-retraf Kinasesras ProteinsReceptor, Notch1Signal TransductionThyroid Carcinoma, AnaplasticBiomarkers, TumorHistone Deacetylase InhibitorsHistone DeacetylasesNF-kappa BNOTCH1 protein, humanProtein Kinase InhibitorsProto-Oncogene Proteins c-retraf Kinasesras ProteinsReceptor, Notch1RET protein, humanAnaplastic thyroid cancerClinical trialsHistone deacetylase inhibitorsKinase inhibitorsNotchThyroid cancer

Identifiers

PMID25260367
PMCPMC4221369
OpenAlexW2125637620

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.